| Factors associated with medication adherence in patients with chronic obstructive pulmonary disease T Agh, A Inotai, A Meszaros Respiration 82 (4), 328-334, 2011 | 203 | 2011 |
| Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review T Agh, G Kovács, M Pawaskar, D Supina, A Inotai, Z Vokó Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity 20, 1-12, 2015 | 186 | 2015 |
| Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low-and middle-income countries B Németh, A Molnár, S Bozóki, K Wijaya, A Inotai, JD Campbell, Z Kaló Journal of comparative effectiveness research 8 (4), 195-204, 2019 | 143 | 2019 |
| Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries T Bochenek, V Abilova, A Alkan, B Asanin, I de Miguel Beriain, Z Besovic, ... Frontiers in pharmacology 8, 942, 2018 | 113 | 2018 |
| Trends in the non‐steroidal anti‐inflammatory drug market in six Central–Eastern European countries based on retail information A Inotai, B Hankó, Á Mészáros Pharmacoepidemiology and drug safety 19 (2), 183-190, 2010 | 94 | 2010 |
| Relationship between medication adherence and health-related quality of life in subjects with COPD: a systematic review T Ágh, P Dömötör, Z Bártfai, A Inotai, E Fujsz, Á Mészáros Respiratory Care 60 (2), 297-303, 2015 | 82 | 2015 |
| Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars A Inotai, CPJ Prins, M Csanádi, D Vitezic, C Codreanu, Z Kaló Expert opinion on biological therapy 17 (8), 915-926, 2017 | 66 | 2017 |
| Need for multicriteria evaluation of generic drug policies Z Kaló, AP Holtorf, R Alfonso-Cristancho, J Shen, T Ágh, A Inotai, ... Value in health 18 (2), 346-351, 2015 | 51 | 2015 |
| Pharmaceutical regulation in Central and Eastern European countries: a current review P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, ... Frontiers in pharmacology 8, 892, 2017 | 43 | 2017 |
| Guidance toward the implementation of multicriteria decision analysis framework in developing countries A Inotai, HT Nguyen, B Hidayat, T Nurgozhin, PHT Kiet, JD Campbell, ... Expert review of pharmacoeconomics & outcomes research 18 (6), 585-592, 2018 | 39 | 2018 |
| Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ... BioMed Research International 2018, 2018 | 39 | 2018 |
| Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic … A Inotai, T Ágh, R Maris, D Erdősi, S Kovács, Z Kaló, E Senkus Cancer Treatment Reviews 100, 102264, 2021 | 37 | 2021 |
| The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for … B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, ... Frontiers in public health 9, 671961, 2021 | 37 | 2021 |
| Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology A Inotai, M Pékli, G Jóna, O Nagy, E Remák, Z Kaló BMC Health Services Research 12, 1-7, 2012 | 35 | 2012 |
| Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis A Inotai, B Rojkovich, A Fülöp, E Jászay, T Ágh, Á Mészáros Rheumatology international 32, 963-969, 2012 | 33 | 2012 |
| Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals–an application on improving tender decision making in Indonesia A Inotai, D Brixner, N Maniadakis, I Dwiprahasto, E Kristin, A Prabowo, ... BMC health services research 18, 1-12, 2018 | 30 | 2018 |
| Policy practices to maximise social benefit from biosimilars A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ... J Bioequiv Availab 9 (4), 467-72, 2017 | 24 | 2017 |
| Modelling the burden of disease associated malnutrition A Inotai, M Nuijten, E Roth, R Hegazi, Z Kaló e-SPEN Journal 7 (5), e196-e204, 2012 | 24 | 2012 |
| Osteoporotic fractures may impair life as much as the complications of diabetes Z Vokó, K Gáspár, A Inotai, C Horváth, K Bors, G Speer, Z Kaló Journal of Evaluation in Clinical Practice 23 (6), 1375-1380, 2017 | 21 | 2017 |
| Overview on patient centricity in cancer care © Narbutas, K York, BD Stein, K Magsanoc-Alikpala, Y Majima, Z Kalo, ... Frontiers in pharmacology 8, 698, 2017 | 20 | 2017 |
Tamás Ágh MD, MSc, PhDPrincipal Researcher at Syreon Research Institute; Associate Professor at University of PecsE-mail megerősítve itt: syreon.eu
